Dallas, Texas 02/07/2014 (FINANCIALSTRENDS) – Incyte Corporation (NASDAQ:INCY) is the biopharmaceutical which belongs to the same peer group as Pfizer Inc (PFE), Eli Lilly & Co (LLY), Novartis AG(ADR), Merck(MRK) as well as CTIC Cell Therapeutics. However, this drug maker differs on the molecular technology it adapts to deliver relief to patients who suffer from a variety of diseases which do not as yet have well-established treatment options.
Incyte Corporation (NASDAQ:INCY) develops small molecule drugs for the serious medical needs, which are yet to be met. One of its most noted products is the JAKAFI or ruxolitinib. This is also popular by the name of INCB 18424. Alternatively INC 424 is considered as oral Janus which is associated with Kinase or (JAK) inhibitor ideal for treating patients which are high-risk myelofibrosis. It also includes primary MF besides post-polycythemia vera MF which required intense treatment cycles.
Incyte Corporation (NASDAQ:INCY) also offers other oral treatments suchas the JAK1 and JAK2 inhibitor. It also works with Eli Lilly to provide commercial connect on some of the compounds which are used for the treatment of such diseases as inflammation as well as autoimmune diseases. JAKAFI is sold in the US commercially as well.
MERCK looks for collaboration with INCY
Incyte Corporation(NASDAQ:INCY) has received an expression of interest from Merck(MRK) to collaborate on a program for treating cancer. Merck wants other companies such as Pfizer, Amgen as well as Incyte to investigate one of it’s products- MK-3475 which is a immunotherapy cancer treatment process. These drugs are considered to be innovative because of the experimental nature of the drugs, which will enhance the immune system to fight cancer cells.
Incyte Corporation (NASDAQ:INCY) will be one of the peer groups which will test MRK’s product, which is aimed at treating different classes of cancer, besides working as a single therapy as well as in combination with other prescribed treatments.